In the second installment of our three-part review-preview series of podcasts, we continue an annual tradition by sitting down with Adam Feuerstein, senior biotech writer for STAT, to discuss the year that was in biotech and what to look for in 2018. We talked to Feuerstein about the themes that emerged in 2017, his annual best and worst biotech CEOs, and what he’ll be watching at JPMorgan and beyond.